Literature DB >> 15040450

Generation and characterization of a constitutively active Stat3 protein.

Juan A Barboza1, Shuguang Wang, Timothy S Schaefer.   

Abstract

Stats are latent transcription factors involved in normal cellular signaling in response to cytokine or growth factor stimulation. Constitutive activation of Stats (primarily Stat3 and Stat5) has been implicated in growth dysregulation and oncogenesis. Furthermore, increased activation of Stats has been observed in several human tumors and tumor-derived cell lines. To assess the contribution of aberrant Stat activation in oncogenesis, we have created a chimeric molecule between Stat3beta and a portion of the Herpes simplex virus VP16 activation domain. The resulting protein, Stat3beta-VAD (VP16 activation domain), is tyrosine phosphorylated on Y705 and can bind DNA in the absence of upstream activation by c-Src or epidermal growth factor (EGF). Unlike Stat3alpha and Stat3beta, Stat3beta-VAD robustly activates transcription of several reporter genes without cytokine or growth factor stimulation. In addition, we show marked upregulation of the endogenous c-myc and c-fos genes upon inducible expression of Stat3beta-VAD in COS-7 cells. Our protein displays the constitutive transcriptional activation of Stat3alpha seen in human tumors and will be a valuable tool in screens for Stat3-regulated genes. In response to the established Stat3 involvement in human cancers, Stat3beta-VAD will also facilitate assessing the contribution of other cancer signaling cascades in the context of aberrant Stat3alpha activity in cancer development and progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15040450     DOI: 10.1023/b:mole.0000013503.16301.82

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  42 in total

1.  Transcription factor Stat5 is an early marker of differentiation of murine embryonic stem cells.

Authors:  C Nemetz; G M Hocke
Journal:  Differentiation       Date:  1998-03       Impact factor: 3.880

2.  Induction of c-fos gene and protein by growth factors precedes activation of c-myc.

Authors:  R Müller; R Bravo; J Burckhardt; T Curran
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

3.  Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

Authors:  R M Weber-Nordt; C Egen; J Wehinger; W Ludwig; V Gouilleux-Gruart; R Mertelsmann; J Finke
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

4.  Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors.

Authors:  R Karni; R Jove; A Levitzki
Journal:  Oncogene       Date:  1999-08-19       Impact factor: 9.867

5.  The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter.

Authors:  B J Wagner; T E Hayes; C J Hoban; B H Cochran
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

6.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.

Authors:  S K Chai; G L Nichols; P Rothman
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

7.  Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor.

Authors:  F W Quelle; W Thierfelder; B A Witthuhn; B Tang; S Cohen; J N Ihle
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

8.  Jak-STAT signaling induced by the v-abl oncogene.

Authors:  N N Danial; A Pernis; P B Rothman
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

9.  Interleukin-3 signals through multiple isoforms of Stat5.

Authors:  M Azam; H Erdjument-Bromage; B L Kreider; M Xia; F Quelle; R Basu; C Saris; P Tempst; J N Ihle; C Schindler
Journal:  EMBO J       Date:  1995-04-03       Impact factor: 11.598

10.  STAT3 is required for the gp130-mediated full activation of the c-myc gene.

Authors:  N Kiuchi; K Nakajima; M Ichiba; T Fukada; M Narimatsu; K Mizuno; M Hibi; T Hirano
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

View more
  4 in total

1.  Investigation of the interaction between CREB-binding protein and STAT4/STAT6.

Authors:  Mingxiang Zhang; Zhou Fu; Daiyin Tian; Enmei Liu; Jihong Dai; Lijia Wang
Journal:  Mol Biol Rep       Date:  2010-12-08       Impact factor: 2.316

2.  Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.

Authors:  Ellen D Renner; Stacey Rylaarsdam; Stephanie Anover-Sombke; Anita L Rack; Janine Reichenbach; John C Carey; Qili Zhu; Annette F Jansson; Julia Barboza; Lena F Schimke; Mark F Leppert; Melissa M Getz; Reinhard A Seger; Harry R Hill; Bernd H Belohradsky; Troy R Torgerson; Hans D Ochs
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

3.  Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration.

Authors:  Anthony L Schwartz; Ramiro Malgor; Eric Dickerson; Ashani T Weeraratna; Andrzej Slominski; Jacobo Wortsman; Norikazu Harii; Aimee D Kohn; Randall T Moon; Frank L Schwartz; Douglas J Goetz; Leonard D Kohn; Kelly D McCall
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 12.531

4.  TLR signaling inhibitor, phenylmethimazole, in combination with tamoxifen inhibits human breast cancer cell viability and migration.

Authors:  Anthony L Schwartz; Eric Dickerson; Nilesh Dagia; Ramiro Malgor; Kelly D McCall
Journal:  Oncotarget       Date:  2016-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.